Explore

Trendline Trendline
Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions

Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions

Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions
Trendline Trendline
Turn Therapeutics Publishes Study on GX-03's Efficacy in Inflammatory Skin Disease Model

Turn Therapeutics Publishes Study on GX-03's Efficacy in Inflammatory Skin Disease Model

Turn Therapeutics Publishes Study on GX-03's Efficacy in Inflammatory Skin Disease Model
Trendline Trendline
Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment

Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment

Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment
Trendline Trendline
InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Veradermics to Present Phase 2/3 Study Results of VDPHL01 for Pattern Hair Loss at World Congress

Veradermics to Present Phase 2/3 Study Results of VDPHL01 for Pattern Hair Loss at World Congress

Veradermics to Present Phase 2/3 Study Results of VDPHL01 for Pattern Hair Loss at World Congress
Trendline Trendline
Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment

Archeus Technologies Begins Phase 1 Trial for Metastatic Cancer Treatment
Trendline Trendline
Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval
Trendline Trendline
Nielsen BioSciences Reports Successful Phase 3 Trial of CANDIN for Wart Treatment

Nielsen BioSciences Reports Successful Phase 3 Trial of CANDIN for Wart Treatment

Nielsen BioSciences Reports Successful Phase 3 Trial of CANDIN for Wart Treatment
Trendline Trendline
Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer

Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer

Antengene Initiates Phase III Study for ATG-022 in Advanced Gastric Cancer
Trendline Trendline
Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances

IDEAYA Biosciences to Participate in 2026 Jefferies Global Healthcare Conference Highlighting Precision Medicine Advances